BioAge Labs (BIOA) Operating Income (2023 - 2026)
BioAge Labs' (BIOA) quarterly Operating Income came in at -$29.3 million in Q2 2026, down 18.42% year-over-year from -$36.0 million in Q2 2025, and down 15.6% quarter-over-quarter from -$25.4 million in Q1 2026.
Analysis
BioAge Labs (BIOA) Operating Income (2023 - 2026) Analysis & Trends
BioAge Labs has disclosed Operating Income across 4 years of filings, most recently posting -$29.3 million for Q2 2026.
- In Q2 2026, Operating Income fell 18.42% year-over-year to -$29.3 million; the TTM figure through Jun 2026 stood at -$106.3 million (down 16.36% YoY), while the FY2025 annual figure was -$92.8 million, down 18.65% from the prior year.
- Operating Income came in at -$29.3 million for Q2 2026 at BioAge Labs, down from -$25.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$9.9 million in Q3 2023 to a low of -$29.3 million in Q2 2026.
- Average Operating Income over 4 years is -$20.8 million, with a median of -$23.9 million recorded in 2024.
- Year-over-year, Operating Income slumped 150.33% in 2024 and grew 6.51% in 2025.
- Over 4 years, Operating Income stood at -$13.6 million in 2023, then slumped by 86.54% to -$25.4 million in 2024, then declined by 12.07% to -$28.4 million in 2025, then dropped by 3.2% to -$29.3 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$29.3 million in Q2 2026, -$25.4 million in Q1 2026, and -$28.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -1.55 Mn |
| 10 | BioAge Labs | 439.00 Mn | 439.00 Mn | -14.23 Mn | -29.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.33 Mn |
| Mar 31, 2026 | -25.38 Mn |
| Dec 31, 2025 | -28.42 Mn |
| Sep 30, 2025 | -23.14 Mn |
| Jun 30, 2025 | -24.77 Mn |
| Mar 31, 2025 | -16.45 Mn |
| Dec 31, 2024 | -25.36 Mn |
| Sep 30, 2024 | -24.75 Mn |
| Jun 30, 2024 | -15.27 Mn |
| Mar 31, 2024 | -12.81 Mn |
| Dec 31, 2023 | -13.60 Mn |
| Sep 30, 2023 | -9.89 Mn |